Long-Term Evaluation of BIIB067 (Tofersen)

NCT03070119 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Interventions

DRUG: Tofersen

Sponsor

Biogen

Collaborators

[object Object]